NADAC acquisition cost data for BAQSIMI 3 MG SPRAY. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00002614501 | $269.39 | 2022-02-23 | Rx |
| 00002614502 | $269.39 | 2022-02-23 | Rx |
| 00002614511 | $269.39 | 2022-02-23 | Rx |
| 00002614501 | $269.39 | 2022-02-23 | Rx |
| 00002614502 | $269.39 | 2022-02-23 | Rx |
| 00002614511 | $269.39 | 2022-02-23 | Rx |
| 00002614501 | $269.39 | 2022-02-23 | Rx |
| 00002614502 | $269.39 | 2022-02-23 | Rx |
| 00002614511 | $269.39 | 2022-02-23 | Rx |
| 00002614501 | $269.39 | 2022-02-23 | Rx |
Generic: Glucagon | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $1.2M | 2,562 | 2,259 | $284.11 |
| 2020 | $9.0M | 17,732 | 13,510 | $287.85 |
| 2021 | $14.3M | 27,996 | 20,497 | $291.95 |
| 2022 | $19.1M | 36,946 | 25,807 | $294.42 |
| 2023 | $25.5M | 48,621 | 32,681 | $295.57 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $3.1M | 5,571 | 3,841 |
| Pennsylvania | $1.8M | 3,619 | 2,223 |
| New York | $1.7M | 3,231 | 2,013 |
| Ohio | $1.3M | 2,402 | 1,634 |
| Texas | $1.2M | 2,253 | 1,533 |
| Michigan | $1.1M | 2,134 | 1,566 |
| North Carolina | $1.1M | 2,015 | 1,284 |
| Massachusetts | $1.1M | 2,026 | 1,166 |
| Indiana | $959.2K | 1,998 | 1,354 |
| Florida | $869.0K | 1,622 | 1,120 |
| New Jersey | $794.4K | 1,421 | 945 |
| Illinois | $721.8K | 1,536 | 1,115 |
| Washington | $669.1K | 1,270 | 868 |
| Virginia | $537.6K | 988 | 672 |
| Connecticut | $530.2K | 993 | 708 |
| Louisiana | $524.5K | 1,038 | 632 |
| Wisconsin | $520.0K | 1,075 | 805 |
| Tennessee | $516.3K | 981 | 660 |
| Colorado | $503.3K | 991 | 773 |
| Oregon | $493.4K | 1,013 | 743 |
| Georgia | $464.9K | 897 | 604 |
| Missouri | $461.0K | 1,052 | 653 |
| Minnesota | $416.5K | 866 | 662 |
| Maryland | $338.1K | 656 | 451 |
| Kentucky | $288.0K | 557 | 375 |
| South Carolina | $261.0K | 512 | 379 |
| Alabama | $260.6K | 450 | 289 |
| Arizona | $246.0K | 457 | 360 |
| West Virginia | $230.9K | 411 | 304 |
| New Mexico | $206.6K | 386 | 277 |
| New Hampshire | $201.0K | 357 | 264 |
| Oklahoma | $197.8K | 401 | 243 |
| Maine | $185.7K | 311 | 241 |
| Utah | $174.5K | 311 | 188 |
| Idaho | $151.7K | 307 | 207 |
| Nebraska | $141.7K | 272 | 206 |
| Montana | $138.5K | 250 | 183 |
| Mississippi | $121.7K | 222 | 131 |
| Delaware | $111.6K | 195 | 132 |
| Nevada | $109.5K | 196 | 148 |
| Iowa | $105.5K | 203 | 129 |
| Arkansas | $99.5K | 188 | 141 |
| Puerto Rico | $91.7K | 199 | 123 |
| Kansas | $78.2K | 141 | 114 |
| South Dakota | $76.3K | 138 | 110 |
| North Dakota | $52.8K | 102 | 70 |
| Alaska | $47.4K | 65 | 49 |
| Vermont | $46.7K | 101 | 73 |
| District of Columbia | $37.1K | 67 | 53 |
| Hawaii | $31.2K | 65 | 38 |
| Rhode Island | $27.9K | 51 | 36 |
| Armed Forces Pacific | $9.4K | 16 | 16 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.